Skip to main content
. 2005 Apr;187(7):2278–2285. doi: 10.1128/JB.187.7.2278-2285.2005

TABLE 2.

Oligonucleotides used in this study

Oligonu- cleotide Sequence (5′-3′)a Positionb
683 CAATTTCAATCAATGCTCCCAC NA
1914 GCACATGTCGACTGGATTGGGGTAG 23284-23308
1915 GGTAAATCTAGACATAAGCTTGGTTTT 25218-25190
2106 GCCCTTTCCGATAAATTGCAA 1670646-1670626
2107 ATCGCGGCTAATGGTGCTT 1670549-1670567
2123 AATGGCATGTTGGTCTTGTAAAAG-3′ 20017-20040
2124 CCACCACTTGCCCATGTTG 20112-20094
2277 GCCGGTAGTGTTGATGGA 23172-23189
2278 AGCAAGGCGCCTAGTGCC 25411-25394
2283 TTGATAGAGCTCTTCAAATTT 23510-23530
2284 CATACTCATGAGCTCACCTGT 25494-25474
2363 CCATCGCCGTTTATTTGTTCTT 22553-22574
2364 TGCCGTACAACGTATCACATGA 22677-22656
2398 GATTTTTGGCTTTACTGATCGCTT 23560-23583
2399 CGCAGTACCAATCATATACGGC 23660-23639
2403 GGACAAATGACGCTAGCATAAATG 23449-23472
2404 ACATCGCAAAGGCTTTATGCTAC 23367-23389
2405 AGCGTCATTTGTCCTGCATAGA 23462-23441
2407 AAGCCAAAAAACCAAGTTCTGG 23571-23550
2442 CACTATGATCCCAGAACTTGGTTTT 23540-23564
a

Underlined bases indicate engineered restriction sites.

b

Position in the Pm70 genome (accession number NC_002663). NA, not applicable.